Ones To Watch News
Refine Search
Biotechnology
Privately-held Swiss drug firm Ewopharma it has entered into a strategic commercial collaboration with China’s CStone Pharmaceuticals to gain rights for sugemalimab in Switzerland and 18 Central Eastern European countries (CEE). 28 May 2024
Pharmaceutical
Australia’s Dimerix saw its shares leap 25% to A$0.42 on Monday, as it announced a licensing agreement with Taiba Middle East FZ. 28 May 2024
Pharmaceutical
With its potential to revolutionize type 2 diabetes (T2D) treatment, Chinese firm Innovent Biologics’ (HKG: 1801) mazdutide's success could reshape the landscape of diabetes therapeutics in China. 25 May 2024
Pharmaceutical
Following the release of an American Society of Clinical Oncology (ASCO) abstract on Thursday, Verastem Oncology’s shares were up 50% in aftermarket trading. 25 May 2024
Biotechnology
Oncology-focused biotech company Tango Therapeutics is to discontinue development of its TNG348 program due toxicity observed in the initial study cohorts. 24 May 2024
Biotechnology
Californian company Cytokinetics closed Thursday’s trading down 17% after announcing a couple of updates that will add $1 billion to its cash pile. 24 May 2024
Pharmaceutical
Sweden-based metabolic disorders company Atrogi, has announced a publication in the Journal of Molecular Metabolism of a research paper that validates the mechanism of action of the company’s first-in-class, small molecule, ATR-127, in combating obesity and metabolic complications. 24 May 2024
Biotechnology
SynaptixBio, a UK biotech that claims to be the world’s only company developing a therapy for TUBB4A-related leukodystrophies, has appointed Uwe Meya as chief medical officer (CMO). 23 May 2024
Biotechnology
Privately-held Chinese developer of molecular glue degraders for cancer treatment Degron Therapeutics has entered into a collaboration and exclusive license agreement with Japan’s largest drugmaker Takeda Pharma. 23 May 2024
Pharmaceutical
Basel, Switzerland-based SixPeaks Bio emerged from stealth mode yesterday, with a pipeline of therapies for healthy weight loss, including a potentially best-in-class dual-specific antibody targeting activin type IIA and B receptors. 23 May 2024
Pharmaceutical
Anglo-American pharma Bicycle Therapeutics was trading 20% higher early on Thursday. 23 May 2024
Biotechnology
Massachusetts, USA-based Nona Biosciences has entered into a license agreement with British pharma major AstraZeneca. 23 May 2024
Biotechnology
hares of French immunotherapy company OSE Immunotherapeutics were up almost 15% at 8.33 euros mid-morning on news of an expand partnership with German family-owned pharma major Boehringer Ingelheim. 23 May 2024
Biotechnology
Cell engineering company MaxCyte has entered into a strategic platform license agreement with Legend Biotech, another company focused on cell therapies. 23 May 2024
Biotechnology
Shares of UK immune-oncology company Roquefort Therapeutics rose almost 24% to 5.51 pence this morning, following the signing of a term sheet to out-license its Midkine antibody portfolio to Dubai-based PDC. 23 May 2024
Biotechnology
SpyBiotech, a biotechnology company specializing in innovative vaccine platforms, has entered into a research agreement with the University of Oxford. 23 May 2024
Biotechnology
The US Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation for Descartes-08. 22 May 2024
Biotechnology
US immunology specialist AltruBio announced an oversubscribed Series B financing of up to $225 million. 22 May 2024
Biotechnology
AI-driven precision medicine company Exscientia has announced a headcount reduction of between 20% and 25%. 22 May 2024
Pharmaceutical
Rhythm Pharmaceuticals, a US biopharma specializing in rare neuroendocrine diseases, has announced that its drug Imcivree (setmelanotide) is expected to be funded and available for use in England and Wales within three months through the National Health Service (NHS) in specialist centers. 22 May 2024
Pharmaceutical
Marking its second deal this month alone, Novo Nordisk has entered into a multi-year collaboration with Massachusetts, USA-based Photys Therapeutics to develop novel proximity-based therapeutics for a cardiometabolic disease target. 18 December 2024
Biotechnology
Cara Therapeutics and Tvardi Therapeutics have announced a definitive agreement to merge, creating a new entity under the Tvardi name. 18 December 2024
Pharmaceutical
SiteOne Therapeutics has announced the completion of a $100 million series C financing, led by Novo Holdings, with participation from OrbiMed, Wellington Management, Mission BioCapital, and others. 18 December 2024
Biotechnology
Flagship Pioneering-founded genome engineering biotech Tessera Therapeutics today announced an investment of up to $50 million from the Bill & Melinda Gates Foundation to develop curative, globally accessible in vivo genetic therapies for sickle cell disease. 18 December 2024
Biotechnology
San Francisco-based Indapta Therapeutics, a privately held start-up developing next-generation cell therapies, has raised $22.5 million in a new financing round. The firm raised over $50 million in series A funding in 2022. 18 December 2024
Biotechnology
French CNS specialist Theranexus saw its shares leap more than 34% to 0.65 euros as it revealed a license and supply agreement with Exeltis to commercialize TX01, its novel formulation of a compound already approved in the indication for the treatment of rare neurological diseases. 18 December 2024
Biotechnology
Shares in US biopharma Viridian Therapeutics shot up by 21% on Monday. 17 December 2024
Biotechnology
US antivirals giant Gilead Sciences today revealed it has entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets with Californian biotech Terray Therapeutics. 17 December 2024
Pharmaceutical
Swedish biotech company Inify Laboratories has raised approximately 135 million kroner ($12.3 million) through a private placement, supporting a planned expansion into the UK. 16 December 2024
Biotechnology
Dewpoint Therapeutics and ConcertAI have announced the first phase of their translational oncology partnership, aligned around the former company's latest drug candidate, DPTX3186. 16 December 2024
Biotechnology
Bicycle Therapeutics, a UK-headquartered pharma company developing a new class of therapeutics based on its proprietary bicyclic peptide technology, closed a third lower on Friday. 16 December 2024
Biotechnology
In a filing with the US financial regulator, German mRNA specialist BioNTech has noted the lifting of a partial clinical hold on its PRESERVE-003 trial. 16 December 2024
Biotechnology
VectorY Therapeutics, a Netherlands-based biotech focused on neurodegenerative diseases, has appointed Jim Scibetta as chief executive officer. 16 December 2024
Biotechnology
Sino-American biotech BeiGene has announced it has entered into a global licensing agreement with China’s CSPC Zhongqi Pharmaceutical Technology for SYH2039, a novel methionine adenosyltransferase 2A (MAT2A)-inhibitor being explored for solid tumors. 13 December 2024
Pharmaceutical
US biotech Corcept Therapeutics has reported positive results from the Phase IV CATALYST study of Korlym (mifepristone) in people with hypercortisolism and difficult-to-control type 2 diabetes. 13 December 2024
Biotechnology
Nine months out from landing an additional $35 million in seed funding, Relation has more news – a big pharma collaboration. The group has announced a $45 million upfront deal, including a $15 million equity investment with UK pharma group GSK. 13 December 2024
Pharmaceutical
UK-based Tenpoint Therapeutics and Seattle’s Visus Therapeutics have announced the completion of their merger to create an entirely new chapter in ophthalmic therapeutic medicines aimed at rejuvenating the aging eye. 12 December 2024
Biotechnology
AI-driven biotech BenevolentAI has announced sweeping changes aimed at refocusing its operations and extending its financial runway into 2027. 12 December 2024
Biotechnology
USA-based Elevation Oncology, an innovative oncology company focused on the discovery and development of selective cancer therapies, has entered into a licensing agreement with Synaffix, part of Swiss out-sourcing major Lonza. 12 December 2024
Pharmaceutical
US clinical-stage drug developer Keros Therapeutics’ shares plummeted more than 73% to $18.20 in pre-market activity on revealing a setback for a lead investigational candidate. 12 December 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze